Company Filing History:
1 out of 1 
1 out of 4 Years Active: 2015
Title: The Innovative Contributions of Johannes Jan Moes in Pharmaceutical Sciences
Introduction
Johannes Jan Moes, an inventive mind from Amsterdam, Netherlands, has made significant strides in the field of pharmaceutical compositions. With a focus on treating neoplastic diseases, his work emphasizes the importance of combining various therapeutic agents to enhance treatment efficacy.
Latest Patents
Moes holds a noteworthy patent that details pharmaceutical compositions and methods aimed at treating neoplastic diseases. This patent includes a combination of a taxane, specifically docetaxel, with a CYP3A4 inhibitor, such as ritonavir. The innovative methods of treatment outlined in the patent involve either simultaneous or separate administration of these agents. Furthermore, the patent encompasses kits designed to facilitate these methods and includes solid pharmaceutical taxane compositions for oral administration, which comprise a substantially amorphous taxane, a carrier, and a surfactant.
Career Highlights
Throughout his career, Moes has engaged in several prestigious organizations. He has gained valuable experience at Slotervaart Participaties B.V. and the Netherlands Cancer Institute. His tenure at these institutions allowed him to collaborate and innovate in the pharmaceutical sector, particularly in the realm of cancer treatment.
Collaborations
Collaboration has been crucial in Moes's career. Notably, he has worked alongside esteemed colleagues such as Jacob Hendrik Beijnen and Johannes Henricus Matthias Schellens. These partnerships have enhanced his research and development efforts, pushing the boundaries of current cancer therapies.
Conclusion
Johannes Jan Moes stands out as an inventor dedicated to advancing medical science, particularly in the treatment of neoplastic diseases. His innovative approaches and collaborations have not only contributed to his patent portfolio but also reflect a persistent quest for improved healthcare solutions. The impact of his work underscores the importance of innovation in the pharmaceutical industry.